A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC01-HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2) - Triumvira Immunologics | Engineered T Cell Therapies
INTRODUCTION
• The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re-direction of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex, with the goal of eliciting a safe and durable anti-tumor response. In preclinical models, TAC-engineered T cells effectively eradicate tumor cells in vitro and in vivo without toxicities typically associated with engineered T cell products. TAC01-HER2 is an autologous T-cell product comprising T cells expressing the HER2 TAC, which specifically recognizes HER2+ cells.
• TACTIC-2 (NCT04727151) is an open-label, multicenter phase I/II study that aims to establish safety, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), pharmacokinetic profile, and efficacy of TAC01-HER2 in patients with HER2-positive solid tumors by immunohistochemistry that are 1+, 2+, or 3+ (i.e. breast, lung, pancreatic, colorectal, gastric, endometrial, ovarian, and others) who have progressed on prior anti-cancer therapies.
• We present updated preliminary data from Cohorts 1-4 (20 participants) that highlights safety and efficacy data; the study further elucidates potential therapeutic impact on patients with HER2 overexpressed solid tumors.
[A Phase 1/2 Study Investigatin ..](/content/cl738/ "A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic CLDN18.2+ Solid Tumors"/index.html) [Development of GUCY2C-TAC T Ce ..](/content/rd347/ "Development of GUCY2C-TAC T Cells for the Treatment of Colorectal Cancer"/index.html)